Pharma Marketing Network

In the future, will the FDA also be pulled into social media by a major Rx drug recall? What can the drug industry learn from the FDA's use of social media and will FDA's example help guide the industry toward best practices in this area? This article describes FDA's social networking initiatives in context of these questions.

In this article, Kim Slocum, former Director, Strategic Planning & Business Development at AstraZeneca describes several alternative future health care system scenarios and makes a case for the industry to support Comparative Effectiveness Research or CER.

This article summarizes the results of the 'How to Earn Back the Public's Trust' survey hosted by Pharma Marketing News between February 4, 2009 and March 14, 2009 , including selected comments from respondents and other commentators.

Welcome to the March 2009 issue of Pharma Marketing News.

Welcome to the March 2009 issue of Pharma Marketing News.

As reported in today's Wall Street Journal: "A document dated Feb. 12, 1997, describes internal company deliberations over how to report 'Study 15,' a...

Good morning, Pharma Marketing Blog fans! It's Friday and that means it's time for the Bob (Ehrlich) vs John (Mack) Friday Morning Smackdown! Every...

Pity the poor FDA! Despite its use of social and other "New" media, the FDA is not equipped to keep up with the new...

Yesterday, I posted a notice about FDA sending GSK a warning letter citing a violative Avodart "Planetarium" TV commercial for exaggerating the benefit of...

At yesterday's 3rd Pharmaceutical Search Engine Marketing Strategies Conference hosted by ExL Pharma, I was able to ask a question about the convergence of...